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Purpose
This statement contains cohesive practical 
guidelines for the indications, contraindications, 
methodology and interpretation of 6 minute walk 
test (6MWT). The authors are convinced that 
these guidelines may also be helpful in the Na-
tional Health Fund (Narodowy Fundusz Zdrowia) 
reimbursement issues (procedure No 89.387 — 
spirometry with 6 minute walk test).
The document has been prepared by the 
Polish Respiratory Society Task Force recruited 
from the members of the PRS Respiratory Phy-
siopathology section in the form of a consensus 
statement.
Background
Disability related to progressive functional 
impairment is one of the most important con-
sequences in chronic conditions, particularly in 
chronic cardiovascular and respiratory diseases. 
Exercise intolerance is a widely accepted measure 
of the degree of disability [1]. Thus, in many di-
seases, assessment of exercise tolerance is an im-
portant element in the evaluation of the patient.
Functional classifications may provide some 
information about the physical condition of the 
patient. The New York Heart Association (NYHA) 
classification is widely used in patients with heart 
failure [2], for patients with chronic obstructive 
pulmonary disease the Medical Research Coun-
cil (MRC) dyspnea scale is recommended. [3]. 
Nevertheless, this is a subjective evaluation and 
in the majority of cases, objective measures are 
more important and have a higher value.
Cardiopulmonary exercise test is a complex 
test performed on a treadmill or cycle ergometer. 
Walk tests are a simple alternative method which 
also allow to assess exercise response [4]. 6 minu-
te walk test is the most commonly used, however 
there are various test modalities which include 
different time durations (e.g. 12 minute walk test), 
fixed distance, step test or shuttle walk test [5].
6MWT is currently widely used to evaluate 
functional capacity. It may more adequately re-
flect patient’s activity than complex tests as the 
level of exercise is comparable to that perfor-
med on a daily basis [6]. The main advantage of 
simple exercise tests is that they do not require 
equipment and may thus be performed in most 
healthcare centers. However, they provide little 
information on the cause of limited exercise tole-
rance. Only when certain evident signs occur may 
the differentiation be possible, e.g. chest pain may 
indicate heart disease, while a decrease in oxygen 
saturation (SpO2) strongly suggests a respiratory 
background.
Indications and limitations
According to the American Thoracic Socie-
ty (ATS) the main indication for 6MWT is the 
assessment of response to medical interventions 
in patients with mild to moderate chronic respi-
ratory or cardiovascular disease [7].
The most important indications for 6 MWT 
are presented in Table 1.
The absence of a disease or clinical condition 
listed above does not indicate that the 6MWT is 
not the optimal and only exercise test that may 
be applied in the given situation.
Controversies concerning the role of 6MWT 
in the qualification for lung resection in patients 
with lung cancer may serve as an example. 
Despite optimistic initial observations on the 
prognostic role of 6MWT in these patients [81], 
guidelines do not indicate 6MWT as the method 
of choice in the assessment of exercise capacity 
and the cardiopulmonary exercise test (CPET) 
with maximal oxygen uptake (VO2max) is prefer-
red [82−87]. However, considering the limited 
availability of CPET in Poland, 6MWT should be 
performed as a screening test in such patients. 
In patients with a  significant decrease in the 
 6 minute walk distance (6MWD), CPET should 
be performed before the disqualification from 
surgery for lung cancer. Of note, a 6MWD of 500 
m corresponds roughly with a VO2max of 15 ml/
kg/min [84, 88], a value which is considered the 
cut-off point for surgery by most experts in the 
field. [85, 87, 89].
In some situations, 6MWT may be the only 
exercise test that the patient is able to perform. 
This may refer to patients with intellectual disa-
bility and mental disorders.
Contraindications
Table 2 presents the most relevant contrain-
dications for the 6MWT [4, 7, 90].
Majority of the recommendations for the 
contraindications do not come from randomi-
zed clinical trials and have the form of sug-
gestions with special regard to safety issues. 
Stable coronary heart disease in not a  con-
traindication for 6MWT, however the patient 
should receive his or her standard treatment 
prior to the test and short acting nitrates must 
readily be available [7].
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Table 1.  Indications and potential applications of the 
6MWT
Evaluation of functional capacity (single measurement)
COPD [8]
Pulmonary hypertension [9−11]
Heart failure [12−15]
Cystic fibrosis [16, 17]
Interstitial lung diseases [18, 19]
Peripheral arterial disease [20]
Parkinson’s disease [21, 22]
Brain injury (e.g. stroke) [23−25]
Elderly disabled patients [26−28]
Intellectual disability [29, 30] and mental disorders [31, 32]
Fibromyalgia [33]
Recovery after abdominal surgery [34]
Qualification for medical interventions and/or follow-up
Lung resection
Lung transplantation [35−38]
Lung volume reduction surgery (LVRS) [39, 40]
Pulmonary rehabilitation [41−46]
Rehabilitation in other conditions [47]
COPD [48–51]
Pulmonary hypertension [52, 53]
Heart failure [14, 54, 55]
Predicting survival
Heart failure [56, 57]
COPD [58−60]
Primary pulmonary hypertension [61−63]
Peripheral arterial disease [64−66]
Chronic liver diseases [67], qualification for liver transplantation 
[68]
Lung injury in other conditions:
Radiation-induced pulmonary toxicity [69]
Evaluation of functional capacity in children [70, 71]
Pulmonary hypertension [72]
Evaluation of selected metabolic parameters [73]
Diabetes mellitus [74]
Cerebral palsy [75], neuromuscular diseases [76-79]
Qualification for lung transplantation in cystic fibrosis [80]
Literature data indicate that 6MWT is a safe 
procedure. Despite the large number of tests 
performed, there are no reports on serious com-
plications, even in patients with heart failure and 
other diseases [6, 91−93].
Recommendation
1. The most important absolute contraindica-
tion for 6MWT is the period of < 7−10 days 
from primary coronary angioplasty due to 
STEMI and < 24 h from elective angioplasty.
Methodology
The 6 minute walk test should be performed 
along a  straight and flat corridor with a hard 
surface and a  length of 30 m [7]. This corridor 
length was applied in the majority of large studies 
involving 6MWT [55, 56, 92, 94−98], however 
other lengths have also been used: 20−25 m [13, 
14, 57, 99], 45−50 m [100, 101], 90 m [102] and 
125 m [103]. The walking distance may be shor-
ter in shorter corridors because of more turns to 
change direction are needed [7]. A study in pa-
tients with COPD demonstrated that the 6MWD 
was approximately 13 m longer when the test 
was performed on a 40 m circular course when 
compared to a straight 30 m corridor [104].
Performing the test on a  treadmill is not 
recommended [7]. A  comparative analysis of 
a 12 minute walk test in a 40 m corridor and on 
a treadmill showed that the distance walked was 
longer during the test on the corridor (791 ± 224 
m vs. 742 ± 224 m), however the difference did 
not reach statistical significance [105]. Swerts 
et al. also noted a longer distance during the 12 
minute walk test performed in a corridor than on 
a treadmill [106]. Other authors confirmed that 
Table 2. Contraindications for the 6MWT
Absolute Relative
< 7−10 days from primary angioplasty due 
to STEMI
< 24 h from elective coronary angioplasty
Resting heart rate 
> 120/min
Acute myocarditis or pericarditis Systolic blood 
pressure  
> 140 mm Hg
Symptomatic arrhythmias Diastolic blood 
pressure  
> 90 mm Hg
Acute deep venous thrombosis, pulmonary 
embolism, pulmonary infarction
Acute heart failure
Acute infectious diseases or other con-
ditions which may have relevant impact on 
the capability of performing the test (e.g. 
severe anemia, acute renal or liver failure, 
hypo- or hyperthyroidism etc.)
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the distance covered during the test on a corridor 
is significantly longer than that on a  treadmill 
(374.3 ± 77.7 m vs. 323.1 ± 118.6) [107]. Ela-
zzazi et al., however, did not find any difference 
between the distance walked in the corridor and 
the treadmill [108]. In all the three mentioned 
studies a motorized treadmill was used and the 
treadmill speed could be modified. Janaudis-Fer-
reira et al. who compared the performance in tests 
performed in the corridor and on a non-motorized 
treadmill found that the distance covered in the 
corridor was 153 m longer [109].
The advantage of the 6MWT on a treadmill is 
that it can be conducted in small spaces.
Required equipment
6MWT does not have complicated equipment 
requirements. The following are necessary:
 — straight 30 m long corridor with a hard sur-
face. It is recommended that the corridor 
should be at least 2−3 m wide and seldom 
travelled. The course should be marked 
every 2 m
 — two colored cones which mark the starting 
point and the end of the lap
 — timer
 — sphygmomanometer
 — pulse oximeter
 — a chair/wheelchair
 — a worksheet to note the number of laps or 
a mechanical lap counter (Appendix 1)
 — a big-font reprint of the Borg scale (Appendix 2)
 — a set of encouraging instructions (Appendix 3)
 — referral form (Appendix 4)
 — signed informed consent of the patient (Ap-
pendix 5).
The evaluation of oxygen saturation during 
6MWT is an important element of the test. 
A number of studies published recently indicate 
that there is a relationship between SpO2 decrease 
during the test and the BODE index [110], the de-
gree of airflow limitation [111, 112], mortality risk 
[111]. Hypoxemia during exercise is very common 
in patients with chronic respiratory diseases [48]. 
Two types of SpO2 variability during the walk test 
have been documented: a gradual decline with 
a plateau and return to baseline after the test is 
completed; a decline at the beginning of the test 
with subsequent increase during exercise (SpO2 at 
the end of the test is usually lower than baseline 
and, at the same time, higher than the lowest 
value recorded during the test) [48, 113, 114]. 
To obtain a  reliable evaluation of oxygen satu-
ration during 6MWT, a continuous SpO2 moni-
toring during the whole test is recommended. 
The better quality of recordings form the finger 
clip than earlobe sensor [115, 116], differences 
in the measurement accuracy of various devices 
[117−119] and the potential influence of other 
factors on the measurements should be conside-
red [120, 121].
For safety reasons, the following should be 
provided:
 — the possibility of immediate contact with 
the physician responsible for conducting 
exercise tests or the attending physician of 
the patient
 — access to an oxygen source
 — access to a resuscitation kit.
Recommendations
2. The 6-minute walk test should be perfor-
med in a flat and straight corridor with 
a hard surface and a length of 30 m.
3. Performing the 6MWT on a treadmill is not 
recommended.
4. The walking course should be marked 
every 2 m.
5. Continuous oxygen saturation monitoring 
during 6MWT is indicated.
Methodology of the test
Patient preparation:
 — the patient should carefully read and sign the 
informed consent form
 — repeated tests (if indicated) should be perfor-
med at the same time of the day
 — pre-test warm-up is not recommended
 — the patient should refrain from intensive 
exercise within 2 hours before the test
 — loose, comfortable clothing which does not 
affect mobility should be worn
 — comfortable non-slip shoes are necessary. 
The test should not be performed in slippers, 
high-heel shoes or barefoot
 — the test should be performed after a light meal 
(depending on the time of the day) and admi-
nistration of the patient’s daily medication
 — if necessary, usual walking aid (e.g. cane, 
walker, corset) should be used during the test
Recommendations
6. The patient should carefully read and sign 
the informed consent form.
7. Repeated tests should be performed at the 
same time of the day.
8. Pre-test warm-up is not recommended.
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9. The patient should refrain from intensive 
exercise within 2 hours before the test.
10. Loose, comfortable clothing which does not 
affect mobility should be worn.
11. Comfortable non-slip shoes are necessary. 
The test should not be performed in slip-
pers, high-heel shoes or barefoot.
12. The test should be performed after a light 
meal (depending on the time of the day) 
and administration of the patient’s daily 
medication.
13. If necessary, usual walking aid (e.g. cane, 
walker, corset) should be used during the test.
Technical aspects
1. The presence of a physician during 6MWT 
is not mandatory, however it is indicated in 
high-risk patients
2. The patient should rest in a sitting position 
for 5−10 minutes before the test, near the 
starting point. During this time:
 — patient preparation and potential contraindi-
cations for the test should be checked
 — arterial blood pressure and heart rate should 
be measured and recorded
 — oxygen saturation should be evaluated
 — Borg scale should be used to assess dyspnea 
(all measurements should be noted on the 
test worksheet)
 — the principles of the test should be explained 
to the patient. It is recommended that every 
patient is provided with exactly the same 
information on the test:
The aim of the test is to walk as far as possi-
ble for 6 minutes. You will be asked to walk back 
and forth along this corridor. The exercise you 
will perform during these six minutes is intensive, 
therefore you may feel short of breath or tired. You 
may slow down or even stop and lean against the 
wall to rest if necessary, but please resume walking 
as soon as you can [7].
The patient should then get prepared to start 
the test:
Are you ready to start? Once you start, the 
counter will be turned on and you will hear it click 
with every turn, this will be noted on the worksheet. 
Remember that you are supposed to walk as fast 
as possible for 6 minutes, so do not jog or run. You 
may start, when you are ready.
1. The technician should stand close to the star-
ting point and start the counter the moment 
the patient starts walking. It is not recom-
mended to walk with the patient.
2. The supervising technician should not be 
distracted and click the lap counter in an 
expressive manner (for encouragement) or 
note every turn on the worksheet. Every stop 
and rest should also be noted. The stopwatch 
should not be turned off for the time of the 
rest — this time is included in the duration 
of the 6MWT.
3. Encouragement of the patient during the 
test is strongly recommended. An even tone 
should be used for standard phrases [7]. 
The motivation should be customized to 
the patient profile. For example, a 10-year 
old child and a 75-year old COPD patient 
with basic education as well as a 40-year old 
patient with lung fibrosis require a different 
set of encouragement phrases. Motivation 
should be used at one-minute intervals and 
15 s before the end of the test. An example 
of encouragement sentences is given below:
First minute:
You are doing very well. There are 5 minutes left.
Second minute:
Your pace is very good. You have 4 more minutes 
to go.
Third minute:
You are doing good. Half of this test is done.
Fourth minute:
Your pace is very good. There are only 2 minutes 
left .
Fifth minute:
Keep on walking like this. There is only one mi-
nute to go.
15 s to the end of the test:
You will be asked to stop in a few moments. When 
you stop, please wait for me at the point you fi-
nished the test.
If the patient stops during the test:
Please rest, you may lean against the wall, if you 
need to. Continue walking as soon as you are able.
4. After six minutes, the technician should say 
loudly: Please stop. If the patient appears 
exhausted providing him/her with a chair or 
wheelchair should be considered.
5. Immediately after the end of the test:
 — SpO2, heart rate and arterial blood pressure 
should be measured and recorded on the test 
worksheet
 — dyspnea should be reported (Borg scale). If 
the patient stopped during the test, the reason 
why he/she needed to rest should also be 
noted in the study protocol.
 — the distance walked should be calculated by 
adding the distance from the number of laps 
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(1 lap = 60 m) and number of meters in the 
final lap. The distance should be rounded to 
the nearest meter.
 — the patient should be congratulated on 
the effort and offered a  rest with a  glass 
of water.
Recommendations
14. The presence of a physician during 6MWT 
is not mandatory, however it is indicated 
in high-risk patients.
15. The principles of the 6MWT should be 
explained to the patient. It is recommended 
that every patient is provided with exactly 
the same information on the test.
16. Before the 6MWT test:
 — patient preparation and potential contra-
indications for the test should be checked
 — arterial blood pressure and heart rate sho-
uld be measured
 — oxygen saturation should be evaluated
 — Borg scale should be used to assess dyspnea
       All measurements should be noted on the 
test worksheet.
17. Every stop and rest should also be noted. 
The stopwatch should not be turned off for 
the time of the rest — this time is included 
in the duration of the 6MWT.
18. To improve effort, the use of standardized 
encouragement phrases with an even tone 
during the test is recommended. Motiva-
tion should be customized to the patient 
profile. Encouragement should be used at 
one-minute intervals and 15 s before the 
end of the test.
19. Post-walk evaluation should be done im-
mediately after exercise and include:
SpO2, heart rate and arterial blood pressure
 — dyspnea (Borg scale)
 — distance walked (calculation with 1 meter 
accuracy)
 — reason for stopping exercise, if the patient 
stopped during the test
All the above should be recorded in the 
study protocol.
Factors influencing 6MWD
Like many other diagnostic test, the result 
of 6MWT may be influenced by various factors 
(Table 3).
Methodological factors affecting 6MWD 
which may be modified include learning effect, 
the experience of the supervising technician and 
encouragement intensity during the test.
Table 3. Factors influencing the distance covered during 
6MWT [7]
6MWD reduction
 older age [28]
 shorter height
 elevated body weight
 female sex
 lack of motivation, depression
 shorter corridor (more turns) [122]
 inappropriate walking shoes [123]
 cognitive disorders
 chronic respiratory diseases [124, 125]
 chronic vascular diseases [126]
 chronic musculoskeletal disorders
6MWD increase
 taller height
 male sex
 strong motivation (encouragement during the test)
 experience in the test performance
 pre-test administration of medication for disabling disease
 supplemental oxygen in patients with exercise induced hy-
poxemia, HeO2 use [127]
Learning effect
Despite a substantial number of studies which 
address the reproducibility of 6MWT, it is still not 
clear if performing a practice test is necessary. 
According to literature data a practice test may 
increase 6MWD by 7−17% [8, 100, 107, 128, 129].
In the opinion of the experts from the ATS, 
a practice test is not necessary in most clinical 
settings. Nevertheless, if it is performed, there 
should be an interval of at least 1 hour between 
the two tests and the higher 6MWD should be 
reported [7].
Recommendations
20. Practice tests are not necessary in patients 
who achieve normal 6 MWD values in the 
first test.
21. Practice tests should be considered in:
 — patients who have a relatively short 6MWD, 
which does not correspond with their ge-
neral condition.
 — patients in whom the result of 6MWT may 
have significant practical implications, e.g. 
qualification for transplantation, lung resec-
tion, modification of medical interventions
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 — elderly patients with impairment of motor 
coordination in whom simple maneuvers 
(turns) may by problematic
 — clinical study participants.
22. There is no evidence for the usefulness of 
more than 2 practice tests
 — practice tests and 6MWT should be perfor-
med within a period no longer than 7 days
 — when performed the same day, an interval 
of at least one hour should be kept between 
subsequent tests
 — the longest recorded distance should be 
considered as the result of the 6MWD.
Technician experience
The laboratory staff should be trained by the 
person responsible for exercise tests; training in 
basic life support is also strongly recommended. 
Quality control should be performed every 6 mon-
ths. Quality control is mandatory as it may affect 
the results of 6MWD. In a study which involved 
4 centers and more than 2000 elderly patients, 
the differences in the methodology of the test 
(including the application of encouragement) in 
two centers resulted in a 7% shorter distance [92].
Recommendations
23. The laboratory staff should be trained by 
the person responsible for exercise tests.
24. Technician training in basic life support is 
also strongly recommended.
25. Quality control should be performed by the 
person responsible for exercise tests every 
6 months.
Encouragement
The use of encouragement as described in 
the methodology section is recommended. As 
previously mentioned, encouragement can impro-
ve the walking distance by approximately 30 m. 
[130]. ATS experts, however, do not recommend 
encouraging patients to walk as fast as possible, 
as applied by some authors [100]. Such a motiva-
tion may lead to a higher walking speed, earlier 
termination of exercise and excessive stress for 
the cardiorespiratory system. [7].
Oxygen supplementation
When the patient requires oxygen supple-
mentation and repeated tests are necessary, the 
use of the same source and oxygen flow during the 
walk test is recommended. The mode of oxygen 
therapy and oxygen flow should be recorded in 
the study protocol. Disregarding oxygen supple-
mentation during 6MWT leads to misinterpreta-
tion of its result.
Interpretation
6MWT is performed as a single test to assess 
the functional status of the patient or it may 
be repeated to evaluate the impact of medical 
intervention (change in treatment regimen, re-
habilitation, oxygen supplementation) on the 
patient’s exercise performance.
The final result of the test should comprise 
the following information:
 — Basic patient data: 
• name
• age
• height, weight
 — Indication for 6MWT
 — Data on methodology of the test
• corridor length
• for tests performed on a treadmill: speed, 
acceleration mode
• for test performed with oxygen supple-
mentation: oxygen source and oxygen flow
 — Walk distance
• absolute value and percent of predicted 
value; information on the author and so-
urce of the reference value should also be 
provided
• information on the number of stops/time 
of rest during the test if applicable
 — Heart rate
• at rest
• at peak exercise (6 min.)
 — Blood pressure
• at rest
• at peak exercise (6 min.)
 — Blood oxygen saturation
• at rest
• lowest recorded value
• at peak exercise (6 min.)
• desaturation (the difference between SpO2 
at rest and SpO2 at peak exercise)
 — Dyspnea according to the Borg scale
• at rest
• at peak exercise (6 min.)
 — Comments of the supervising technician
Recommendations
26. The final result of the test should comprise 
information on the basic data of the pa-
tient, indications for 6MWT, methodology, 
distance walked and results of the following 
measurements (at rest and at peak exercise, 
i.e. after 6 min.): heart rate, blood pressure, 
blood oxygen saturation and dyspnea.
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Reference values
No uniform reference values for 6MWD have 
been established to date. Table 4 presents the most 
relevant publications on reference values for 6MWD.
The choice of the source of the 6MWD re-
ference equations is the decision of the exercise 
laboratory team; the reference population should 
correspond to the study population.
Recommendation
27. The choice of the source of the 6MWD 
reference equations is the decision of the 
exercise laboratory team; the reference 
population should correspond to the study 
population
Single measurement interpretation — 
assessment of functional status
Both absolute and percent of predicted va-
lues of 6MWD should be considered during the 
interpretation of the result of 6MWT. Despite 
a number of factors modifying 6MWD, the abso-
lute value of the distance walked provides useful 
information. In patients with COPD, 6MWD is 
used to calculate the BODE index, which defines 
prognosis in this disease. The cut-off values for 
6 MWD applied for the stratification of functional 
impairment severity are 350 m, 250 m and 150 m 
[60]. In patients with COPD, absolute 6MWD is an 
important predictor for mortality, with the lowest 
risk for patients who achieve a distance longer 
than 400 m [58]. Earlier studies on patients quali-
fied for lung resection, reported cut-off values of 
300 m [81] and 450−500 m [83, 89] for predicting 
postoperative complications.
In patients with Eisenmenger’s  syndrome, 
6MWD < 350 m is related with a three-fold in-
crease in mortality risk [133].
Another study showed that a 6MWD < 250 m 
in patients with pulmonary hypertension (idio-
Table 4. Reference equations for the 6 minute walk distance.
Author No of patients Age 
(yrs)
Corridor 
length (m)
Formula — men Formula — women r2 of statisti-
cal model
1 Enright  
[97]
290  
(117 M, 173 F)
40−80 30 6MWD (m) = (7.57 × he-
ight) – (5.02 × age) – (1,76 
× body weight) – 309a
6MWD (m) = (2.11 × he-
ight)  
– (2.29 × body weight)  
– (5.78 × age) + 667b
F — 0.38
M — 0.42
2 Troosters  
[100]
51  
(29 M, 21 F)
50−85 50 6MWD (m) = 218 + (5.14 × 
height – 5.32  
× age) – (1.80 × body we-
ight + 51.31)c
6MWD (m) = 218 + (5.14 × 
height – 5.32 × age) – (1.80 
× body weight)c
0.66
3 Camarri 
[101]
70  
(33 M, 37 F)
55−75 45 6MWD (m) = 216.9  
+ (4.12 x height) – (1.75 × 
age) – (1.15 × body weight)
6MWD (m) = 216.9 + (4.12 
× height) – (1.75 × age) – 
(1.15 × body weight) – 34.04
0.36
4 Gibbons  
[131]
79  
(41 M, 38 F)
20−80 20 6MWD (m) = 868.8  
– (age × 2.99)
6MWD (m) = 868.8 – (age 
× 2.99) – 7.47
0.41
5 Enright  
[92]
2117  
(853 M, 1264 
K)
≥ 68 30 6MWD (m) = 493 + (2.2  
× height) – (0.93 × body 
weight) – (5.3 × age) + 17d
6MWD (m) = 493 + (2.2  
× height) – (0.93 × body 
weight) – (5.3 × age)d
0.2
6 Chetta  
[98]
102  
(48 M, 54 F)
20−50 30 6MWD (m) = 518.53 + 
(1.25 × height) – (2.816 × 
age)
6MWD (m) = 518.53 + 
(1.25 × height) – (2.816 × 
age) – 39.07
0.42
7 Casanova  
[93]
444  
(238 M, 206 F)
40−80 30 6MWD (m) = 361 – (age×4) 
+ (height×2) + (HRmax%HR-
MAX×3)  
– (body weight×1.5)
6MWD (m) = 361 – (age×4) 
+ (height×2) + (HRmax%HR-
MAX×3) – (body weight×1.5) 
– 30
0.38
8 Geiger  
[99]
456  
(208 M, 248 F)
3−18 20 6MWD (m) = 196.72  
+ (39.81×age) – 
(1.36×age^2 ) + 
(13.28×height)
6MWD (m) = 188.61  
+ (51.50×age) – 
(1.86×age^2 ) + 
(86.10×height)
M — 0.49
F — 0.50
9 Prusak 
[132]
545 (261 M, 
284 F)
7−18 the test was 
performed in 
a 20 × 30 m 
sports hall
6MWD (m) = 374.9  
+ (2.22×age) + (3.53×he-
ight)  
– (1.71×body weight)
6MWD (m) = 419.8  
+ (14.99×age) + (2.56×he-
ight) – (3.03×body weight)
M — 0.54
F — 0.48
HRmax%HRMAX — heart rate at peak exercise at the end of 6MWT (HRmax) expressed as percent of predicted maximal heart rate (HRMAX) calculated as follows 
HRMAX = 220-age 
ato calculate lower limit of normal (LLN) subtract 153 from obtained value 
bto calculate lower limit of normal (LLN) subtract 139 from obtained value 
cresidual standard deviation (RSD) = 56 m 
dto calculate lower limit of normal (LLN) subtract 100 from obtained value
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pathic and related with interstitial lung disease) 
is associated with a 50% mortality risk within 
2 years [62]. In patients with idiopathic pulmona-
ry hypertension, the 6MWD cut-off value which 
predicts survival was established at 332 m [61]. 
According to experts from the American College of 
Cardiology, an increase in 6MWD to ≥ 380−440 m 
should be one of the goals of treatment in idiopa-
thic pulmonary hypertension [11].
In patients with heart failure, 6MWD < 300 m 
is associated with a significantly higher mortality 
compared to patients with 6MWD > 300 m (10% 
vs. 3%) [56]. Significant differences in mortality 
risk were also observed in patients with 6MWD 
< 300 m, 300−450 m and > 450 m [134].
A decrease in 6MWD is also a  significant 
prognostic factor in idiopathic pulmonary fibrosis 
(IPF). Lederer et al. showed that in patients with 
IPF, a 6MWD < 207 m (considering the influence 
a number of other factors) is related with a four-fold 
higher mortality [63]. Another study showed that 
the cut-off value for 6MWD which defines func-
tional impairment and has a significant impact on 
mortality risk in patients with IPF is 350 m [135].
Despite of a number of reference equations 
proposed by various authors, no algorithm for 
the interpretation 6MWD expressed as percent 
of predicted value has been established to date. 
Troosters et al. propose that a 6MWD below 82% 
of predicted value should be treated as abnormal 
[100]. The lower limit of normal for 6MWD may 
be calculated from equation 1[97] or 5 [92] pre-
sented in Table 4.
Equation 2 [100] may be applied for the cal-
culation of residual standard deviation with the 
use of the following formula.
SR=(actual value–predicted value)/RSD
Changes in blood oxygen saturation
Desaturation during 6MWT may indicate 
gas exchange impairment during exercise [136, 
137]. A decrease of SpO2 by ≥ 4% or SpO2 < 88% 
or 90% during exercise is considered clinically 
significant [4, 138, 139].
Interpretation — minimal important 
difference
Although numerous studies addressed the 
impact of medical interventions on 6MWT, it is 
still not clear if the changes in 6MWD should be 
expressed as an absolute value, relative diffe-
rence or as the difference in percent of predicted 
value. It seems that presenting the difference as 
an absolute value is optimal, as it enables com-
parative analysis with other studies which may 
use different reference equations. 
The evaluation of the potential effect of medi-
cal interventions is strictly related to the so called 
minimal important difference — MID or minimally 
clinically important difference — MICD which is 
used to describe the minimal significant change 
in 6MWD which is associated with improvement/
deterioration of functional performance reported 
by the patients.
Many authors apply the MID cut-off value of 
54 m (95% CI 37−71 m) proposed by Riedelmeier 
et al. who analyzed a group of 112 patients with 
COPD [140]. In other studies, the MID ranged 
between 26 and 80 m [141−143]. In the ECLIP-
SE study, a > 30 m decrease in 6MWD within 
12 months was associated with a higher mortality 
risk (hazard ratio 1.93) [96].
In elderly patients with heart failure, the 
reported MID was 24−48 m, depending on the 
self-reported change in functional performance 
(slight improvement — significant deteriora-
tion)[144].
In patients with pulmonary hypertension, 
an MID of 33 m was established with a  range 
of 25−39 m depending on the reference equ-
ation applied [145]. The MID for patients with 
idiopathic pulmonary hypertension is 24−45 
m, and a decrease of > 50 m in 6MWD within 
24 weeks is a negative prognostic factor and is 
related with an at least four-fold higher morta-
lity risk [146].
Impact of interventions on 6MWD
One of the first reports on 6 MWT showed 
that supplemental oxygen (2 L/min and 4 L/min) 
improved 6MWD by 51 m and 75 m, respectively, 
however when portable oxygen was applied, the 
improvement was irrelevant [147]. Leach et al. 
demonstrated that the use of portable liquid oxy-
gen with FiO2 0.28, 0.4 and 0.53 resulted in an 
increase in 6MWD by 19.2%, 34.5% and 36.3% 
when compared to the test performed with the 
use of an oxygen cylinder of a similar weight as 
the device with liquid oxygen. Moreover, the 
degree of desaturation as well as dyspnea were 
lower [129].
Pulmonary rehabilitation is reported to in-
crease 6MWD by 40−48 m [124, 148].
Lung volume reduction surgery increases the 
6MWD by approximately 55 m [149].
Rehabilitation also improves exercise perfor-
mance in patients with cardiovascular diseases; 
a 6MWD increase of approximately 60 m may be 
observed [150].
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Recommendations
28. A significant decrease in 6MWD is defined 
as a decline < 82% of predicted value or 
below the lower limit of normal.
29. A  decrease of SpO2 ≥ 4% (as compared 
to SpO2 at rest) or below 88% (or 90%) is 
considered clinically significant.
30. Disease specific minimal important diffe-
rence (MID) should be considered in the 
analysis of the impact of medical interven-
tions on 6MWD.
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Appendix 1
start end
HR
RR
SpO2
Dyspnea
Distance
Laps
Stops:
1 — duration s, reason:
2 — duration s, reason:
3 — duration s, reason:
4 — duration s, reason:
5 — duration s, reason:
Appendix 2
Referral for the 6 minute walk test and patient consent form
REFERRAL FOR THE 6 MINUTE WALK TEST
Institution: .................................tel. ......................................
Patient name: ...........................Age: ......................................
ID No:  ..................Case history No: ......................................
Indication for 6MWT: .............................................................................................................................
.................................................................................................................................................................
Concomitant diseases:
1. None
2.  Concomitant diseases which may influence the course of the test (musculoskeletal disorders in 
particular)................................................................................................................................................
.................................................................................................................................................................
I DECLARE NO CONTRAINDICATIONS FOR THE 6 MINUTE WALK TEST.
Date and signature of the referring physician
Attention: Information for the patient and the consent form are on the reverse page
INFORMATION for the patient
The aim of the study is to walk the longest distance possible during 6 minutes. You will be walking along the corridor 
between two marked points. During the test you may slow down or stop if necessary but you should continue walking 
as soon as you can, so that the distance walked in 6 minutes will be as long as possible. The technician will inform 
you about the time from the start of the test and about the time left to the end. Directly before and immediately after 
the test your blood pressure, heart rate and oxygen saturation with a finger sensor will be measured. You will also be 
asked to evaluate your dyspnea in a 10-point scale.
The distance walked in 6 minutes expressed in meters is the result of the test.
PATIENT CONSENT FORM
I, ..........................................................................................
have read and understood the above information on the test, had the opportunity to ask additional 
questions, understood and accepted the given answers. I agree to perform the test and give my consent 
for storing my personal data.
Signature
Study protocol
6 minute walk test 30 meter corridor
Name ID No Date
Age Body weight 
(kg)
Height  
(cm)
Protocol 
No
Indication
Start time:
Comments:
Polish Respiratory Society guidelines for the methodology (6MWT)
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Appendix 3
INFORMATION FOR THE PATIENT
The aim of the test is to walk as far as possible for 6 minutes. You will be asked to walk back and forth 
along this corridor. The exercise you will perform during these six minutes is intensive, therefore you 
may feel short of breath or tired. You may slow down or even stop and lean against the wall to rest if 
necessary, but please resume walking as soon as you can.
Are you ready to start? Once you start, the counter will be turned on and you will hear it click with every 
turn, this will be noted on the worksheet. Remember that you are supposed to walk as fast as possible 
for 6 minutes, so do not jog or run.
You may start, when you are ready.
Appendix 4
Encouragement
 — only the standardized encouragement phrases presented below should be used
 — an even tone during motivation is recommended
 — the technician should not talk to the patient or to the potential observers during the test
First minute:
You are doing very well. There are 5 minutes left.
Second minute:
Your pace is very good. You have 4 more minutes to go.
Third minute:
You are doing good. Half of this test is done.
Fourth minute:
Your pace is very good. There are only 2 minutes left .
Fifth minute:
Keep on walking like this. There is only one minute to go.
15 s to the end of the test:
You will be asked to stop in a few moments. When you stop, please wait for me at the point you finished 
the test.
If the patient stops during the test:
Please rest, you may lean against the wall, if you need to. Continue walking as soon as you are able to.
Appendix 5
Borg dyspnea scale
0 nothing at all
1. very, very slight
2. very slight
3. slight
4. moderate
5. somewhat severe
6. severe
7. very severe
8. 
9. very, very severe
10. maximal
